Who Paid My Doc
Thomas Sneed
Hematology & Oncology Little Rock, AR Medical Doctor
NPI 1053317941 CMS profile 274667
8901 Carti Way, Little Rock, AR 72205
General payments
$874
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Thomas Sneed of Little Rock, AR is reported in the CMS Open Payments database as having received $874 across 16 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 34th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $115 | 4 | |
| 2024 | General | $427 | 5 | |
| 2023 | General | $18 | 1 | |
| 2022 | General | $24 | 1 | |
| 2021 | General | $23 | 2 | |
| 2019 | General | $267 | 3 |
Beside peers
- Thomas Sneed
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Thomas Sneed were reported at $115. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Thomas Sneed | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $267 | $529 | $121–$2,516 | $163 |
| 2020 | $0 | $339 | $82–$2,213 | $114 |
| 2021 | $23 | $263 | $49–$1,965 | $132 |
| 2022 | $24 | $416 | $103–$2,395 | $149 |
| 2023 | $18 | $542 | $125–$2,646 | $160 |
| 2024 | $427 | $692 | $141–$3,008 | $164 |
| 2025 | $115 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 89 drugsPart D claims
4,530
Drug cost
$12,864,424
Branded share of claims
39.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Calquence Acalabrutinib Maleate | Brand | 127 | $1,906,666 | |
| Imbruvica Ibrutinib | Brand | 74 | $1,200,767 | |
| Jakafi Ruxolitinib Phosphate | Brand | 70 | $1,050,928 | |
| Inlyta Axitinib | Brand | 45 | $948,149 | |
| Ibrance Palbociclib | Brand | 61 | $926,893 | |
| Venclexta Venetoclax | Brand | 55 | $597,975 | |
| Keytruda Pembrolizumab | Brand | 52 | $589,856 | |
| Tasigna Nilotinib Hcl | Brand | 27 | $517,433 | |
| Cabometyx Cabozantinib S-Malate | Brand | 17 | $428,040 | |
| Stivarga Regorafenib | Brand | 19 | $405,864 |
The 10 drugs with the highest cost, of 89 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 202 billing codesPaid by Medicare
$4,499,260
Medicare patients
1,226
Services billed
277,538
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 53% | |
| Arthritis | 45% | |
| Ischemic heart disease | 38% | |
| Diabetes | 33% | |
| Chronic kidney disease | 27% | |
| Heart failure | 25% | |
| Depression | 24% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 23 | 19,400 | $850,420 |
| Injection, nivolumab, 1 mg J9299 | Office | 13 | 15,060 | $370,899 |
| Injection, denosumab, 1 mg J0897 | Office | 24 | 4,800 | $93,148 |
| Injection, rituximab-arrx, biosimilar, (riabni), 10 mg Q5123 | Office | 11 | 2,250 | $72,505 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 25 | 2,700 | $42,300 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 | Office | 30 | 2,793 | $15,897 |
| Injection, aprepitant, 1 mg J0185 | Office | 17 | 6,500 | $8,689 |
| Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram Q5125 | Office | 19 | 19,200 | $7,596 |
| Injection, bortezomib (velcade), 0.1 mg J9041 | Office | 11 | 3,430 | $4,855 |
| Injection, leucovorin calcium, per 50 mg J0640 | Office | 14 | 1,165 | $3,878 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
16 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Arkansas
Eric Schaefer
Hematology & Oncology · Fayetteville, AR
Frits Van Rhee
Hematology & Oncology · Little Rock, AR
Isam Abdel-Karim
Hematology & Oncology · Fort Smith, AR
Appalanaidu Sasapu
Hematology & Oncology · Little Rock, AR
Stephan Rosenfeld
Hematology & Oncology · Fayetteville, AR
Stephen Divers
Hematology & Oncology · Hot Springs, AR
Related records
Hematology & Oncology in Arkansas
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Arkansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.